SWOG researchers to present practice-changing research at virtual ASCO 2021 SWOG always brings an impressive portfolio of work to the ASCO annual meeting, said SWOG Chair Charles D. Blanke, MD, and this year I m particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing.
Investigators will present 12 abstracts from SWOG-led or co-led studies and 11 abstracts from studies led by other groups within the National Clinical Trials Network (NCTN).
Results from S1216 will be presented orally by study chair Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah. S1216 compared androgen deprivation therapy (ADT) combined with TAK-700 to the standard treatment of ADT with bicalutamide in patients who had metastatic hormone-sensitive prostate cancer. The study found that adding TAK-700 to ADT lengthened median progression-free survival in these patients and improved prostate-specific
A hematology oncologist at OU Health Stephenson Cancer Center is the co-leader of a national clinical trial that could revolutionize the field of bone marrow transplant with an imaging technique that provides an early look at a transplant s likely success or failure.
E-Mail
IMAGE: Darla Kendzor, Ph.D., co-director of the TSET Health Promotion Research Center, was recently awarded a 5-year, $3.1 million grant from the National Cancer Institute to evaluate the effectiveness of an. view more
Credit: OU Health
OKLAHOMA CITY -Darla Kendzor, Ph.D., co-director of the TSET Health Promotion Research Center, was recently awarded a 5-year, $3.1 million grant from the National Cancer Institute to evaluate the effectiveness of an automated, smartphone-based approach to incentivizing smoking cessation among low-income adults in Oklahoma.
Kendzor s past work has uncovered the detrimental impact that financial stress, neighborhood problems, and discrimination can have on smoking cessation. Recently, her work has focused on developing and evaluating practical and effective smoking cessation interventions for vulnerable Oklahomans.
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Dr. O Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms. view more
Credit: University of Pennsylvania
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficiency on genomic testing and tumors that express the
LAG-3 protein, a cancer immunotherapy target. The cancer must also have progressed on anti-PD-1/PD-L1 immunotherapy. The addition brings the number of available treatment arms in NCI-MATCH to 12. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health, are co-leading